Award
National Cancer Institute 5R44CA278176-02
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
Recipient
UP THERAPEUTICS, INC.
Award Amount
$1,178,998.00
Ceiling
$1,178,998.00
Awarded
July 31, 2024
Identifier
5R44CA278176-02
Award for developing a novel small molecule RPN13 inhibitor as a therapeutic for advanced ovarian cancer, funded by the National Cancer Institute under NIH with a total funding of approximately $1.18 million.
Description
The project involves developing a small molecule RPN13 inhibitor for ovarian cancer. The award is part of NIH's efforts to fund innovative cancer therapeutics. The project includes multiple aims such as toxicity assessment, efficacy testing, process development, and safety studies. The project is funded under the PA-22-176 funding opportunity. The organization involved is UP THERAPEUTICS, INC., located in Frederick, MD. The project duration is from September 1, 2023, to August 31, 2026.